The UK's Medicines and Healthcare products Regulatory Authority (MHRA) has issued a recall for specific batches of both the schizophrenia drug Zyprexa (olanzapine), which is manufactured by US drugmaker Eli Lilly, as well as the hypertension product Plavix (clopidogrel), jointly-marketed in the UK by France's Sanofi-Aventis and the USA's Bristol-Myers Squibb. The announcement follows the discovery of counterfeit product in the legitimate supply chain with falsified French packaging in both cases.
Until the announcement, dated May 24, no proven instance of counterfeit infiltration via the European parallel trade network had been recorded by the MHRA. For the European Association of Euro-Pharmaceutical Companies the timing of the revelation could hardly be less helpful. In the previous week, the European Parliament hosted a symposium on the threat of counterfeit drugs, at which branded drugmakers were at pains to point out what they consider the systematic weakness of the distribution process (Marketletter May 28).
Parallel traded drugs can pass through "20-30 pairs of hands"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze